Table 2.

Clinical features, laboratory tests, treatment, follow up and immunohistochemical and genetic features of 16 cases of nodal pediatric DLBCL including GC and non-GC types.

Case n°	Sex	Age	AL	S	LDH	BM	CNS	MC	IP	QT	RTX	RT	BMT	FUP	CD20	CD10	BCL6	BCL2	MUM1	TCL1	MIB	CMYC
1	F	10	C,I	IV	NA	P	N	BRT	GC	CHOP×8	YX8	N	N	19	P	N	P	P	N	N	50%	N
2	M	15	A	I	NO	N	N	CB	GC	BFM×4	N	N	N	6	P	N	P	P	N	N	90%	N
3	M	16	M	II	H<2	N	N	CB	GC	CHOP×6	N	Y	N	38	P	P	N	P	N	N	80%	I
4*	M	15	I	II	NA	N	N	UC	GC	HCVAD	N	N	N	18	P	P	P	P	N	P	80%	P
5	F	13	A	III	NO	N	N	CB	GC	BFM×6	N	N	N	36	P	P	P	N	N	P	90%	P
6	M	10	C	II	NO	N	N	BRT	GC	BFM×4	N	N	N	31	P	N	P	N	N	N	50%	P
7	M	16	RP	II	NO	N	N	CB	GC	BFM×4	N	N	N	24	P	P	P	N	P	P	80%	N
8	F	12	C, A	IV	H<2	N	P	CB	GC	BFM×6	N	Y	N	19	P	N	P	N	N	N	40%	N
9	M	16	M, C	IV	H<2	P	N	CB	GC	BFM×6	N	Y	N	40	P	N	P	N	N	N	80%	N
10	M	15	M, A,I	IV	NO	P	N	CB	GC	ICE×4	YX6	N	AT	18	P	N	P	P	N	N	70%	P
11	M	15	A, RP	III	H>2	N	N	CB	NO-GC	BFM×5	ICEYX5	N	N	12	P	N	N	P	P	N	70%	N
12	F	15	M	III	NA	N	N	CB	NO-GC	CHOP×2	N	N	N	1	P	N	P	P	P	N	40%	N
13	F	17	M, C	II	H<2	N	N	CB	NO-GC	BFM×6	N	N	N	12	P	N	P	P	P	N	30%	N
14	F	18	C	IV	H>2	N	P	IB	NO-GC	CHOP×8	CHOP YX8	N	N	36	P	N	P	P	P	N	90%	N
15	F	12	RP, I, A	IV	H>2	N	N	CB	NO-GC	BFM×6	N	N	N	44	P	N	P	N	P	P	80%	P
16	M	18	RP	III	N	N	N	CB	NO-GC	BFM×8	N	N	N	48	P	N	P	P	P	P	80%	N

Age: in years; AL: anatomic location; S: clinical stage; LDH: lactate deshidrogenase; BM: bone marrow; CNS: central nervous system; MC: morphological classification; IP: immunophenotype; QT: chemotherapy; RTX: rituximab; RT: radiotherapy; BMT: bone marrow transplantion; FUP: follow up; F: female; M: male; C: cervical; I: inguinal; A: axillar; M: mediastinum; RP: retroperitonium; NA: not available; NO: normal; H: high: <2 less than double normal, >2 higher than double normal; P: positive; N: negative; I: inconclusive; Y: yes; CB: centroblastic; IB: immunoblastic; BRT: T-cell rich B-cell lymphoma; UN: unclassified; GC: germinal center type; NO-GC: non-Germinal center type; AT: autologous;

^*case 4 revealed BCL2 translocation by FISH.